文献速递结核与非结核分枝杆菌

在出生时接种卡介苗的乌干达青少年中,ChAdOx1 85A初免后MVA85A加强免疫与卡介苗复种的安全性和免疫原性比较:一项随机、开放标签试验

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
PubMed 文献 · Lancet Infect Dis · 2023-11-25

该随机开放标签2a期试验在乌干达12-17岁出生时接种过卡介苗且无明显结核暴露的健康青少年中比较ChAdOx1 85A-MVA85A与卡介苗复种的安全性及免疫原性。结果显示ChAdOx1 85A-MVA85A组未发生严重不良事件,Ag85A特异性IFN-γ ELISpot反应高于卡介苗复种组,几何均值比为30.59(95%CI 17.46-53.59,p<0.0001)。

要点

  • ChAdOx1 85A-MVA85A组未报告严重不良事件,仅1例严重事件在MVA85A加强后出现且迅速自行缓解。
  • 卡介苗复种组全部30例报告至少1项轻至中度征集性不良事件,多为局部反应。
  • ChAdOx1 85A-MVA85A组第63天Ag85A特异性IFN-γ ELISpot反应高于卡介苗复种组(几何均值比30.59)。

核心结论

  • ChAdOx1 85A-MVA85A方案安全,且诱导的Ag85A特异性反应强于卡介苗复种;作者认为研究结果支持进一步开发结核加强疫苗。

研究设计与样本

  • 在ChAdOx1 85A剂量递增和年龄递减研究后,开展随机、开放标签2a期试验,纳入乌干达Entebbe地区12-17岁、出生时接种过卡介苗且无明显结核暴露的健康青少年。
  • 参与者按1:1随机分配(区组大小6)至ChAdOx1 85A后第56天MVA85A加强组或卡介苗(莫斯科株)复种组,实验室人员对分组设盲。
  • 主要结局为至第28天的征集性和非征集性不良事件、全程严重不良事件,以及针对抗原85A的IFN-γ ELISpot反应(第63天几何均值及第0-224天曲线下面积)。

主要发现

  • 剂量递增和年龄递减阶段共入组6名成人和6名青少年(2019年7月至8月)。
  • 2a期试验共60名青少年随机分配至ChAdOx1 85A-MVA85A组(第5组,n=30)或卡介苗复种组(第6组,n=30;2019年12月至2020年10月)。
  • ChAdOx1 85A-MVA85A组30例中23例(77%)报告60起不良事件,其中31起为全身性,1起严重事件发生在MVA85A加强后且迅速自行缓解;卡介苗复种组全部30例报告至少1项轻至中度征集性不良事件,多为局部反应;两组均无严重不良事件。
  • ChAdOx1 85A-MVA85A组Ag85A特异性IFN-γ ELISpot反应在第63天达峰,且高于卡介苗复种组:第63天几何均值比30.59(95%CI 17.46-53.59),p<0.0001;第0-224天AUC均值差57 091(95%CI 40 524-73 658),p<0.0001。

关键数值与推荐

  • ChAdOx1 85A-MVA85A组 vs 卡介苗复种组:第63天Ag85A特异性IFN-γ ELISpot几何均值比30.59(95%CI 17.46-53.59),p<0.0001,ChAdOx1 85A-MVA85A组更高。
  • ChAdOx1 85A-MVA85A组 vs 卡介苗复种组:第0-224天AUC均值差57 091(95%CI 40 524-73 658),p<0.0001,ChAdOx1 85A-MVA85A组更高。

临床怎么用

  • 作者认为研究结果支持进一步开发结核加强疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BCG confers reduced, variable protection against pulmonary tuberculosis. A more effective vaccine is needed. We evaluated the safety and immunogenicity of candidate regimen ChAdOx1 85A-MVA85A compared with BCG revaccination among Ugandan adolescents. METHODS: After ChAdOx1 85A dose escalation and age de-escalation, we did a randomised open-label phase 2a trial among healthy adolescents aged 12-17 years, who were BCG vaccinated at birth, without evident tuberculosis exposure, in Entebbe, Uganda. Participants were randomly assigned (1:1) using a block size of 6, to ChAdOx1 85A followed by MVA85A (on day 56) or BCG (Moscow strain). Laboratory staff were masked to group assignment. Primary outcomes were solicited and unsolicited adverse events (AEs) up to day 28 and serious adverse events (SAEs) throughout the trial; and IFN-γ ELISpot response to antigen 85A (day 63 [geometric mean] and days 0-224 [area under the curve; AUC). FINDINGS: Six adults (group 1, n=3; group 2, n=3) and six adolescents (group 3, n=3; group 4, n=3) were enrolled in the ChAdOx1 85A-only dose-escalation and age de-escalation studies (July to August, 2019). In the phase 2a trial, 60 adolescents were randomly assigned to ChAdOx1 85A-MVA85A (group 5, n=30) or BCG (group 6, n=30; December, 2019, to October, 2020). All 60 participants from groups 5 and 6 were included in the safety analysis, with 28 of 30 from group 5 (ChAdOx1 85A-MVA85A) and 29 of 30 from group 6 (BCG revaccination) analysed for immunogenicity outcomes. In the randomised trial, 60 AEs were reported among 23 (77%) of 30 participants following ChAdOx1 85A-MVA85A, 31 were systemic, with one severe event that occurred after the MVA85A boost that was rapidly self-limiting. All 30 participants in the BCG revaccination group reported at least one mild to moderate solicited AE; most were local reactions. There were no SAEs in either group. Ag85A-specific IFN-γ ELISpot responses peaked on day 63 in the ChAdOx1 85A-MVA85A group and were higher in the ChAdOx1 85A-MVA85A group compared with the BCG revaccination group (geometric mean ratio 30·59 [95% CI 17·46-53·59], p<0·0001, day 63; AUC mean difference 57 091 [95% CI 40 524-73 658], p<0·0001, days 0-224). INTERPRETATION: The ChAdOx1 85A-MVA85A regimen was safe and induced stronger Ag85A-specific responses than BCG revaccination. Our findings support further development of booster tuberculosis vaccines. FUNDING: UK Research and Innovations and Medical Research Council. TRANSLATIONS: For the Swahili and Luganda translations of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wajja A, Nassanga B, Natukunda A, et al. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Lancet Infect Dis. 2023. PMID: 38012890. doi:10.1016/S1473-3099(23)00501-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。